Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Roche Grants License to Response Biomedical

By HospiMedica staff writers
Posted on 08 Aug 2005
A nonexclusive license to commercialize a key cardiac marker for an array of conditions has been granted by Roche Diagnostics (Basel, Switzerland) to Response Biomedical (Vancouver, Canada).

Specifically, Response Biomedical received a nonexclusive license under patent rights to commercialize NT-proBNP (N-terminal prohormone brain natriuretic peptide). More...
As part of the agreement, Response Biomedical also received an option to commercialize troponin T, a cardiac marker for heart attack, for use with its RAMP system for the point-of-care (POC) market segment.

The availability of test results within minutes is vital for the assessment of patients with suspected cardiac problems. The RAMP system of Response Biomedical provides a quantitative measurement of cardiac markers in whole blood to diagnose a heart attack and provide test results in less than 15 minutes.

"This relationship with Roche Diagnostics enables Response Biomedical to significantly enhance our RAMP cardiac portfolio of FDA-cleared troponin T, CK-MB, and myoglobin tests while expanding our international marketing and distribution network over the coming months,” observed Bill Radvak, president and CEO of Response Biomedical.






Related Links:
Roche Diagnostics
Response Biomedical

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Electrolyte Analyzer
BKE-B
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.